Filtered By:
Drug: Coumadin

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 3661 results found since Jan 2013.

Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population.
CONCLUSIONS: Among the DOACs in the study, only apixaban is associated with a significantly lower risk of stroke/SE and major bleeding and lower related medical costs compared to warfarin. PMID: 28635338 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 22, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
ConclusionPatients receiving dabigatran had significantly lower total all-cause, inpatient, and outpatient costs but higher pharmacy costs than those receiving warfarin. In addition, stroke-specific total and outpatient costs and bleed-specific total and inpatient costs were significantly lower in dabigatran users compared with warfarin users.
Source: American Journal of Cardiovascular Drugs - August 9, 2017 Category: Cardiology Source Type: research

Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation
AbstractAtrial fibrillation (AF) is associated with significant risk of stroke and other thromboembolic events, which can be effectively prevented using oral anticoagulation (OAC) with either vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, or edoxaban. Until recently, VKAs were the only available means for OAC treatment. NOACs had similar efficacy and were safer than or as safe as warfarin with respect to reduced rates of hemorrhagic stroke or other intracranial bleeding in the respective pivotal randomized clinical trials (RCTs) of stroke prevention in non-valvular AF...
Source: Advances in Therapy - September 27, 2017 Category: Drugs & Pharmacology Source Type: research

Stroke Prevention in Atrial Fibrillation - Which is the BEST?: Balanced in Efficacy and Safety as a Thromboprophylactic.
Authors: Suvarna V Abstract Stroke prevention in atrial fibrillation (AF) has reached an exciting phase with a plethora of newer, potentially more efficacious and safer agents being introduced for physicians to select from. Dabigatran belongs to a class of anticoagulants called direct thrombin inhibitors, while rivaroxaban, apixaban, and edoxaban are direct Factor Xa inhibitors. Purely from a therapeutic endpoint perspective-based on the action of anticoagulants in reducing cardioembolic stroke-in clinical trials, one should look at whether a new anticoagulant in patients with AF prevents ischemic stroke. From a ne...
Source: Journal of the Association of Physicians of India - January 11, 2018 Category: General Medicine Tags: J Assoc Physicians India Source Type: research

Stroke Severity in Patients on Non-Vitamin K Antagonist Oral Anticoagulants with a Standard or Insufficient Dose.
CONCLUSION:  Use of warfarin with a therapeutic intensity or standard-dosed NOACs was associated with a relatively mild stroke in the patients with NVAF. PMID: 30453351 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 19, 2018 Category: Hematology Authors: Jung YH, Choi HY, Lee KY, Cheon K, Han SW, Park JH, Cho HJ, Park HJ, Nam HS, Heo JH, Lee HS, Kim YD Tags: Thromb Haemost Source Type: research

Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption
Conclusion Antiplatelet or vitamin K antagonist suspension has a temporal relationship with the occurrence of stroke and TIA. Since these events are preventable, it is crucial that healthcare professionals convince their patients that drug withdrawal can cause serious consequences.RESUMO Pacientes em terapia anticoagulante ou antiagregante plaquet ária frequentemente são solicitados a descontinuar essas medicações antes e durante procedimentos cirúrgicos ou invasivos. Se o paciente interromper tratamento sem supervisão médica, poderá aumentar de risco de acidente vascular cerebral (AVC). Objetivo Identificar preval...
Source: Arquivos de Neuro-Psiquiatria - July 29, 2019 Category: Neurology Source Type: research

Medical Management for Secondary Stroke Prevention
This article reviews the evidence base and recommendations for medical management for secondary stroke prevention. RECENT FINDINGS Recent developments for secondary stroke prevention include evidence to support the use of short-term dual antiplatelet therapy after minor stroke and transient ischemic attack, direct oral anticoagulants for nonvalvular atrial fibrillation, reversal agents for direct oral anticoagulant–associated hemorrhage, and aspirin rather than presumptive anticoagulation with a direct oral anticoagulant for embolic stroke of undetermined source. SUMMARY Most strokes are preventable. The mainstays ...
Source: CONTINUUM: Lifelong Learning in Neurology - April 1, 2020 Category: Neurology Tags: REVIEW ARTICLES Source Type: research

Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin
ConclusionIn NVAF patients of all ages initiating either apixaban or warfarin for stroke prevention in the Sentinel System, apixaban was associated with a decreased risk of GI bleeding, ICH, and ischemic stroke compared with warfarin. Among patients less than 65  years of age, apixaban use was associated with a decreased risk of GI bleeding and ischemic stroke.
Source: Journal of General Internal Medicine - September 27, 2020 Category: Internal Medicine Source Type: research

The Relationship Between Limited English Proficiency and Outcomes in Stroke Prevention, Management, and Rehabilitation: A Systematic Review
ConclusionsStroke patients with LEP face barriers to equitable care at multiple stages. While some studies demonstrate worse outcomes for LEP patients, equitable care was shown in multiple studies frequently in the setting of a high degree of interpreter availability. Patients with LEP will benefit from tailored education regarding stroke symptom recognition and medication regimens, and from provision of translated written educational material. Inequities in inpatient care and rehabilitation exist despite similar mortality rates in four studies. Future studies should report interpreter availability and usage within LEP gro...
Source: Frontiers in Neurology - February 3, 2022 Category: Neurology Source Type: research

Stroke and Systemic Thromboembolism according to CHA < sub > 2 < /sub > DS < sub > 2 < /sub > -VASc Score in Contemporary Korean Patients with Atrial Fibrillation
CONCLUSION: Contemporary AF patients have a stroke rate about one-fifth that in OAC-naïve AF patients and exhibit different stroke risk factors.STUDY REGISTRATION: ClinicalTrials.gov (NCT02786095).PMID:35352882 | DOI:10.3349/ymj.2022.63.4.317
Source: Yonsei Medical Journal - March 30, 2022 Category: Universities & Medical Training Authors: Kyung Bae Lee Tae-Hoon Kim Junbeom Park Jin-Kyu Park Ki-Woon Kang Jun Kim Hyung Wook Park Eue-Keun Choi Jin-Bae Kim Young Soo Lee Jaemin Shim Boyoung Joung Source Type: research